© 2000 by European Society of Cardiology
Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization
Department of Medicine, Sahlgrenska University Hospital, Östra Göteborg, Sweden; 1Department of Cardiology, Karolinska Hospital Stockholm, Sweden; 2Department of Cardiology, Uppsala University Hospital Uppsala, Sweden; 3Department of Cardiology, University Hospital Groningen, The Netherlands; 4Department of Cardiology, Umeå University Hospital Umeå, Sweden; 5Astra-Hässle AB Mölndal, Sweden; 6Division of Cardiology, Sahlgrenska University Hospital, Sahlgrenska Göteborg, Sweden
AIMS: Drug-induced increase in QT dispersion has been associated with increased risk of ventricular proarrhythmia. The aim of the present study was to compare QT dispersion during atrial fibrillation and sinus rhythm in the same patients at normal and prolonged ventricular repolarization.
METHODS AND RESULTS: Sixty-one patients who had had chronic atrial fibrillation for 8±14 months received a 6 h infusion of the Ikr-blocker almokalant, the first 90 min of which are used for this analysis. The following day, after conversion to sinus rhythm, by almokalant (n=19) or direct current cardioversion (n=42), an identical 90 min infusion was administered. Prior to infusion, there was no difference in precordial QT dispersion between atrial fibrillation and sinus rhythm (29±12 vs 36±17 ms, P=ns). During infusion, at prolonged repolarization, the increase in QT dispersion was greater during sinus rhythm than during atrial fibrillation (58±49 vs 30±15 ms,P =0·0011, after 30 min infusion). No correlation was found between QT dispersion and the QT or RR interval.
CONCLUSION: QT dispersion during atrial fibrillation does not differ from QT dispersion during sinus rhythm during normal repolarization, while measurement of QT dispersion during prolonged repolarization, induced by an Ikr-blocker, yielded larger values during sinus rhythm than during atrial fibrillation.
Key Words: QT dispersion, ventricular repolarization, class III antiarrhythmic agent, atrial fibrillation, sinus rhythm, almokalant
Correspondence: Dr Birgitta Houltz, Department of Clinical Physiology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden.
[1] Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992; 70: 1432–1437.[CrossRef][Web of Science][Medline]
[2] Zabel M, Portnoy S, Franz MR. Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 1995; 25: 746–752.[Abstract]
[3] Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994; 89: 1681–1689.
[4] Fu GS, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J 1997; 18: 281–289.
[5] de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97: 467–472.
[6] Houltz B, Darpö B, Edvardsson N. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. PACE 1998; 21: 1044–1057.[Medline]
[7] Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86: 1376–1382.
[8] Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995; 26: 852–858.[Abstract]
[9] Darpö B and Almgren O. Almokalant — a selective class III antiarrhythmic compound. Cardiovasc Drug Rev 1996; 14: 60–83.
[10] Roden DM. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am J Cardiol 1996; 78: 12–16.[Web of Science][Medline]
[11] Bazett H. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353–369.[Web of Science]
[12] Blomström Lundqvist C, Dohnal M, Hirsch I. Effect of long term treatment with metoprolol and sotalol on ventricular repolarisation measured by use of transoesophageal atrial pacing. Br Heart J 1986; 55: 181–186.
[13] Darpö B, Almgren O, Bergstrand R. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal atrial stimulation. J Cardiovasc Pharmacol 1995; 25: 681–690.[Web of Science][Medline]
[14] Bland JM and Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–310.[CrossRef][Web of Science][Medline]
[15] Bland M and Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995; 346: 1085–1087.[CrossRef][Web of Science][Medline]
[16] Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989; 63: 867–869.[CrossRef][Web of Science][Medline]
[17] Dritsas A, Gilligan D, Nihoyannopoulos P, Oakley CM. Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992; 36: 345–349.[CrossRef][Web of Science][Medline]
[18] Grimm W, Steder U, Menz V, Hoffmann J, Maisch B. Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events. Clin Cardiol 1997; 20: 107–110.[Medline]
[19] Meierhenrich R, Helguera ME, Kidwell GA, Tebbe U. Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. Int J Cardiol 1997; 60: 289–294.[CrossRef][Web of Science][Medline]
[20] Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342–344.
[21] Day CP, McComb JM, Matthews J, Campbell RW. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991; 12: 423–427.
[22] Cui G, Sen L, Sager P, Uppal P, Singh BN. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994; 74: 896–900.[CrossRef][Web of Science][Medline]
[23] Demolis JL, Funck Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94: 1592–1599.
[24] Faber TS, Zehender M, Krahnefeld O, Daisenberger K, Meinertz T, Just H. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 1997; 29: 561–567.[Abstract]
[25] Hohnloser SH, van de Loo A, Kalusche D, Arendts W. Does sotalol-induced alteration in QT-dispersion predict drug effectiveness or proarrhythmic hazards? (Abstr). Circulation 1993; 88: 1397.
[26] Dancey D, Wulffhart Z, McEwan P. Sotalol-induced torsades de pointes in patients with renal failure. Can J Cardiol 1997; 13: 55–58.[Web of Science][Medline]
[27] Zareba W and Moss AJ. Dispersion of repolarization. Relation to heart rate and repolarization duration. J Electrocardiol 1995; 28: 202–206.[Medline]
[28] Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 5: 672–685.[Web of Science][Medline]
[29] Hnatkova K, Malik M, Kautzner J, Gang Y, Camm AJ. Adjustment of QT dispersion assessed from 12 lead electrocardiograms for different numbers of analysed electrocardiographic leads: comparison of stability of different methods. Br Heart J 1994; 72: 390–396.
[30] Glancy JM, Weston PJ, Bhullar HK, Garratt CJ, Woods KL, de Bono DP. Reproducibility and automatic measurement of QT dispersion. Eur Heart J 1996; 17: 1035–1039.
[31] Cowan JC, Yusoff K, Moore M. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61: 83–87.[CrossRef][Web of Science][Medline]
[32] Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115–172.[CrossRef][Web of Science][Medline]
[33] Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111: 1088–1093.[CrossRef][Web of Science][Medline]
[34] Antzelevitch C and Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994; 23: 259–277.[Abstract]
[35] Ellenbogen KA, Stambler BS, Wood MA. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28: 130–136.[Abstract]
[36] Waldo AL, Camm AJ, deRuyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348: 7–12.[CrossRef][Web of Science][Medline]
[37] Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995; 49: 159–166.[CrossRef][Web of Science][Medline]
[38] Darpö B, Allared M, Edvardsson N. Torsades de pointes induced by transesophageal atrial stimulation after administration of almokalant. Int J Cardiol 1996; 53: 311–313.[CrossRef][Web of Science][Medline]
[39] Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug. Am Heart J 1993; 126: 1008–1011.[CrossRef][Web of Science][Medline]
[40] Verduyn SC, Vos MA, van der Zande J, Kulcsar A, Wellens HJ. Further observations to elucidate the role of interventricular dispersion of repolarization and early after depolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol 1997; 30: 1575–1584.[Abstract]
[41] Coumel P, Maison-Blanche P, Badilini F. Dispersion of ventricular repolarization. Reality? Illusion? Significance? Circulation 1998; 97: 2491–2493.
[42] Hartel G, Louhija A, Konttinen A, Halonen PI. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J 1970; 32: 57–60.
[43] Faber TS, Zehender M, Van de Loo A, Hohnloser S, Just H. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. Clin Cardiol 1994; 17: 197–202.[Web of Science][Medline]
[44] Arstall MA, Hii JT, Lehman RG, Horowitz JD. Sotalol-induced torsade de pointes: management with magnesium infusion. Postgrad Med J 1992; 68: 289–290.
[45] Choy AMJ, Darbar D, Dell'Orto S, Roden DM. Increased sensitivity to QT prolonging drug therapy immediately after conversion to sinus rhythm. Circulation 1996; 94: 1202.
[46] Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029–1034.[CrossRef][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Darpo, M. Agin, D. J. Kazierad, G. Layton, G. Muirhead, P. Gray, and D. K. Jorkasky Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies? J. Clin. Pharmacol., June 1, 2006; 46(6): 598 - 612. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||